Eli Lilly (LLY.N): The combination therapy of Taltz and Zepbound met its primary endpoint at week 36. The ACR50 response rate of Taltz in combination with Zepbound was three times that of Taltz alone. The combination therapy trial showed that after one year of treatment, the ACR50 response rate reached 43.7%, compared to 15.7% with Taltz alone.
